Sam M. Mbulaiteye, M.D., of the Infections and Immunoepidemiology Branch (IIB), has been awarded scientific tenure by the NIH. His research focuses on unraveling the role of infections, immunity, and genetic factors in the etiology of Burkitt lymphoma (BL) and Kaposi sarcoma. Both of these malignancies are endemic in Africa and their risk is substantially increased in the setting of HIV/AIDS.
Dr. Mbulaiteye received his primary medical degree in 1990 from Makerere University in Kampala, Uganda. He earned an M.Phil. in epidemiology and biostatistics in 1994 from the University of Cambridge in the United Kingdom (U.K.), and received specialization in internal medicine (M. Med.) from Makerere University in 1996
After working at the Uganda Cancer Institute and the Uganda Virus Research Institute, Dr. Mbulaiteye joined IIB as a research fellow in 2000. He is a principal investigator of the Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) study, a multicountry and multiyear case-control study of childhood BL in Uganda, Tanzania and Kenya. The study is providing the opportunity to explore whether genetic resistance to malaria lowers risk of BL, among other questions.
Dr. Mbulaiteye is a member of the Editorial Board for the International Journal of Cancer, Frontiers in Cancer Epidemiology and Prevention, and Co-Editor-in-Chief for Infectious Agents and Cancer. At NCI, he currently serves on the DCEG Genotyping Review Committee and the NIH Tenure-Track Investigators Committee.
Dr. Mbulaiteye is a recipient of the DCEG Outstanding Paper by a Fellow (2003), the NCI Directors Investigator Innovation Award (2008), and the NIH Award of Merit (2008), and was featured in an NCI Special Report: A Journey to Discovery, Journal of Minority Medical Students (2009).